Comprehensive Stock Comparison
Compare Gyre Therapeutics, Inc. (GYRE) vs argenx SE (ARGX) vs Can-Fite BioPharma Ltd. (CANF) vs Akari Therapeutics, Plc (AKTX) vs Abivax S.A. (ABVX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | ABVX | 133.5% revenue growth vs CANF's -9.3% |
| Value | ARGX | Better valuation composite |
| Quality / Margins | ARGX | 23.3% net margin vs ABVX's -21.9% |
| Stability / Safety | CANF | Beta 0.36 vs GYRE's 1.31 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ABVX | +14.8% vs AKTX's -72.9% |
| Efficiency (ROA) | ARGX | 12.9% ROA vs ABVX's -277.5% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Gyre Therapeutics is a pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ fibrosis. It generates revenue primarily from its approved drug ETUARY (Pirfenidone) for idiopathic pulmonary fibrosis, with additional pipeline drugs in various clinical stages targeting liver, lung, and kidney diseases. The company's competitive advantage lies in its specialized focus on fibrosis treatments and its structural derivatives platform that builds on proven anti-fibrotic mechanisms.
argenx is a biotechnology company that develops antibody-based therapies for autoimmune diseases. It generates nearly all its revenue from VYVGART — its FcRn blocker for conditions like myasthenia gravis — with additional income from partnerships and licensing. The company's key advantage is its proprietary antibody engineering platform that creates differentiated therapies with potentially better safety and efficacy profiles.
Can-Fite BioPharma is a clinical-stage biopharmaceutical company developing small molecule drugs targeting inflammatory diseases and cancer. It generates revenue primarily through licensing agreements and milestone payments from partners — with no commercial products yet — as it advances its lead candidates through clinical trials. The company's competitive advantage lies in its proprietary A3 adenosine receptor platform, which targets a novel pathway for treating autoimmune and inflammatory conditions.
Akari Therapeutics is a clinical-stage biopharmaceutical company developing advanced therapies for autoimmune and inflammatory diseases. It generates no revenue currently — its business model depends on advancing its lead candidate nomacopan through clinical trials to eventually secure regulatory approvals and commercialization partnerships. The company's key advantage lies in nomacopan's dual mechanism of action targeting both complement and leukotriene pathways — a differentiated approach that could offer superior efficacy in treating complex inflammatory conditions.
Abivax is a clinical-stage biotechnology company developing novel therapies for inflammatory diseases, infectious diseases, and cancer. It generates revenue primarily through research grants and partnerships while advancing its lead candidate ABX464 through clinical trials for ulcerative colitis, Crohn's disease, and other inflammatory conditions. The company's competitive advantage lies in its proprietary small molecule platform technology that targets RNA biology to modulate inflammation and viral replication.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 5 stocks. BestLagging
Financial Scorecard
ARGX leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). ABVX leads in 1 (Total Returns). 1 tied.
Financial Metrics (TTM)
ARGX and AKTX operate at a comparable scale, with $4.0B and $0 in trailing revenue. ARGX is the more profitable business, keeping 23.3% of every revenue dollar as net income compared to ABVX's -21.9%. On growth, GYRE holds the edge at +19.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | GYREGyre Therapeutics… | ARGXargenx SE | CANFCan-Fite BioPharm… | AKTXAkari Therapeutic… | ABVXAbivax S.A. |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $107M | $4.0B | $560,000 | $0 | $15M |
| EBITDAEarnings before interest/tax | $14M | $95M | -$9M | -$17M | -$358M |
| Net IncomeAfter-tax profit | $7M | $923M | -$9M | -$16M | -$332M |
| Free Cash FlowCash after capex | $1M | $213M | -$8M | -$10M | -$250M |
| Gross MarginGross profit ÷ Revenue | +95.5% | +75.5% | +100.0% | — | +100.0% |
| Operating MarginEBIT ÷ Revenue | +11.2% | -1.0% | -16.0% | — | -23.7% |
| Net MarginNet income ÷ Revenue | +6.2% | +23.3% | -15.7% | — | -21.9% |
| FCF MarginFCF ÷ Revenue | +1.3% | +5.4% | -14.9% | — | -16.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +19.9% | +5.1% | -36.1% | — | -40.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.7% | +12.6% | +36.4% | -80.2% | -144.6% |
Valuation Metrics
At 60.0x trailing earnings, ARGX trades at a 64% valuation discount to GYRE's 164.8x P/E.
| Metric | GYREGyre Therapeutics… | ARGXargenx SE | CANFCan-Fite BioPharm… | AKTXAkari Therapeutic… | ABVXAbivax S.A. |
|---|---|---|---|---|---|
| Market CapShares × price | $711M | $47.5B | $14.2B | $12.6B | $9.6B |
| Enterprise ValueMkt cap + debt − cash | $701M | $46.0B | $14.2B | $12.6B | $9.5B |
| Trailing P/EPrice ÷ TTM EPS | 164.80x | 60.01x | -4.40x | -0.00x | -36.72x |
| Forward P/EPrice ÷ next-FY EPS est. | 44.95x | 25.57x | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 39.49x | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 6.72x | 21.67x | 9999.00x | — | 753.36x |
| Price / BookPrice ÷ Book value/share | 8.57x | 9.09x | 6.34x | 0.00x | 159.73x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
Profitability & Efficiency
ARGX delivers a 15.1% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-2 for CANF. ARGX carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to ABVX's 2.40x. On the Piotroski fundamental quality scale (0–9), GYRE scores 4/9 vs CANF's 1/9, reflecting mixed financial health.
| Metric | GYREGyre Therapeutics… | ARGXargenx SE | CANFCan-Fite BioPharm… | AKTXAkari Therapeutic… | ABVXAbivax S.A. |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +4.8% | +15.1% | -2.1% | -69.4% | -149.0% |
| ROA (TTM)Return on assets | +4.2% | +12.9% | -114.0% | -34.7% | -2.8% |
| ROICReturn on invested capital | +35.1% | -0.5% | -4.5% | -172.5% | — |
| ROCEReturn on capital employed | +16.0% | -0.4% | -108.1% | -142.3% | -98.5% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 | 1 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.02x | 0.01x | 0.02x | 0.15x | 2.40x |
| Net DebtTotal debt minus cash | -$10M | -$1.5B | -$5M | $661,000 | -$47M |
| Cash & Equiv.Liquid assets | $12M | $1.5B | $5M | $3M | $144M |
| Total DebtShort + long-term debt | $2M | $39M | $104,000 | $3M | $97M |
| Interest CoverageEBIT ÷ Interest expense | — | 166.64x | -580.71x | -47.14x | -21.56x |
Total Returns (with DRIP)
A $10,000 investment in ABVX five years ago would be worth $146,121 today (with dividends reinvested), compared to $35 for AKTX. Over the past 12 months, ABVX leads with a +1479.2% total return vs AKTX's -72.9%. The 3-year compound annual growth rate (CAGR) favors ABVX at 144.5% vs AKTX's -67.5% — a key indicator of consistent wealth creation.
| Metric | GYREGyre Therapeutics… | ARGXargenx SE | CANFCan-Fite BioPharm… | AKTXAkari Therapeutic… | ABVXAbivax S.A. |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +21.0% | -8.7% | +2059.1% | -18.6% | -9.3% |
| 1-Year ReturnPast 12 months | -29.0% | +22.8% | +169.9% | -72.9% | +1479.2% |
| 3-Year ReturnCumulative with dividends | +83.1% | +109.5% | +75.3% | -96.6% | +1361.2% |
| 5-Year ReturnCumulative with dividends | -64.4% | +125.2% | -76.5% | -99.6% | +1361.2% |
| 10-Year ReturnCumulative with dividends | -92.6% | +3234.4% | -98.5% | -99.9% | +1361.2% |
| CAGR (3Y)Annualised 3-year return | +22.3% | +28.0% | +20.6% | -67.5% | +144.5% |
Risk & Volatility
CANF is the less volatile stock with a 0.36 beta — it tends to amplify market swings less than GYRE's 1.31 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CANF currently trades 96.3% from its 52-week high vs AKTX's 13.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GYREGyre Therapeutics… | ARGXargenx SE | CANFCan-Fite BioPharm… | AKTXAkari Therapeutic… | ABVXAbivax S.A. |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.31x | 0.44x | 0.36x | 0.63x | 1.07x |
| 52-Week HighHighest price in past year | $13.75 | $934.62 | $4.93 | $1.73 | $148.83 |
| 52-Week LowLowest price in past year | $6.11 | $510.06 | $0.17 | $0.22 | $4.77 |
| % of 52W HighCurrent price vs 52-week peak | +59.9% | +82.1% | +96.3% | +13.7% | +81.5% |
| RSI (14)Momentum oscillator 0–100 | 59.8 | 33.9 | 68.6 | 52.2 | 45.5 |
| Avg Volume (50D)Average daily shares traded | 60K | 301K | 4.3M | 387K | 1.2M |
Analyst Outlook
Analyst consensus: GYRE as "Buy", ARGX as "Buy", CANF as "Buy", AKTX as "Buy", ABVX as "Buy". Consensus price targets imply 12601.1% upside for AKTX (target: $30) vs 17.5% for ABVX (target: $143).
| Metric | GYREGyre Therapeutics… | ARGXargenx SE | CANFCan-Fite BioPharm… | AKTXAkari Therapeutic… | ABVXAbivax S.A. |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $16.00 | $1026.71 | $7.25 | $30.00 | $142.50 |
| # AnalystsCovering analysts | 1 | 35 | 4 | 7 | 8 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Nov 23 | Feb 26 | Change |
|---|---|---|---|
| Gyre Therapeutics, … (GYRE) | 100 | 130.52 | +30.5% |
| argenx SE (ARGX) | 100 | 168.9 | +68.9% |
| Can-Fite BioPharma … (CANF) | 100 | 193.9 | +93.9% |
| Akari Therapeutics,… (AKTX) | 100 | 6.6 | -93.4% |
| Abivax S.A. (ABVX) | 117.59 | 1,342.89 | +1042.0% |
Abivax S.A. (ABVX) returned +1.4K% over 5 years vs Akari Therapeutics,… (AKTX)'s -100%. A $10,000 investment in ABVX 5 years ago would be worth $146,121 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Gyre Therapeutics, … (GYRE) | $2M | $106M | +5943.3% |
| argenx SE (ARGX) | $7M | $2.2B | +29130.4% |
| Can-Fite BioPharma … (CANF) | $164717.00 | $674000.00 | +309.2% |
| Akari Therapeutics,… (AKTX) | $0.00 | $0.00 | — |
| Abivax S.A. (ABVX) | $42000.00 | $11M | +25595.2% |
Gyre Therapeutics, Inc.'s revenue grew from $2M (2015) to $106M (2024) — a 57.7% CAGR. argenx SE's revenue grew from $7M (2015) to $2.2B (2024) — a 87.9% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Gyre Therapeutics, … (GYRE) | -8.4% | 11.4% | +235.5% |
| argenx SE (ARGX) | -2.2% | 38.0% | +1802.4% |
| Can-Fite BioPharma … (CANF) | -29.1% | -11.7% | +59.9% |
| Abivax S.A. (ABVX) | -379.9% | -16.3% | +95.7% |
Gyre Therapeutics, Inc.'s net margin went from -8% (2015) to 11% (2024). argenx SE's net margin went from -2% (2015) to 38% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Gyre Therapeutics, … (GYRE) | -49.99 | 0.05 | +100.1% |
| argenx SE (ARGX) | -1.06 | 12.78 | +1305.7% |
| Can-Fite BioPharma … (CANF) | -81 | -1.08 | +98.7% |
| Akari Therapeutics,… (AKTX) | -10,640 | -1,660 | +84.4% |
| Abivax S.A. (ABVX) | -1.64 | -2.8 | -70.7% |
Gyre Therapeutics, Inc.'s EPS grew from $-49.99 (2015) to $0.05 (2024). argenx SE's EPS grew from $-1.06 (2015) to $12.78 (2024).
Chart 5Free Cash Flow — 5 Years
Gyre Therapeutics, Inc. generated $-7M FCF in 2024 (+92% vs 2021). argenx SE generated $-151M FCF in 2024 (+79% vs 2021).
GYRE vs ARGX vs CANF vs AKTX vs ABVX: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is GYRE or ARGX or CANF or AKTX or ABVX a better buy right now?
argenx SE (ARGX) offers the better valuation at 60.0x trailing P/E (25.6x forward), making it the more compelling value choice. Analysts rate Gyre Therapeutics, Inc. (GYRE) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GYRE or ARGX or CANF or AKTX or ABVX?
On trailing P/E, argenx SE (ARGX) is the cheapest at 60.0x versus Gyre Therapeutics, Inc. at 164.8x. On forward P/E, argenx SE is actually cheaper at 25.6x.
03Which is the better long-term investment — GYRE or ARGX or CANF or AKTX or ABVX?
Over the past 5 years, Abivax S.A. (ABVX) delivered a total return of +1361%, compared to -99.6% for Akari Therapeutics, Plc (AKTX). A $10,000 investment in ABVX five years ago would be worth approximately $146K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ARGX returned +32.3% versus AKTX's -99.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GYRE or ARGX or CANF or AKTX or ABVX?
By beta (market sensitivity over 5 years), Can-Fite BioPharma Ltd. (CANF) is the lower-risk stock at 0.36β versus Gyre Therapeutics, Inc.'s 1.31β — meaning GYRE is approximately 262% more volatile than CANF relative to the S&P 500. On balance sheet safety, argenx SE (ARGX) carries a lower debt/equity ratio of 1% versus 2% for Abivax S.A. — giving it more financial flexibility in a downturn.
05Which has better profit margins — GYRE or ARGX or CANF or AKTX or ABVX?
argenx SE (ARGX) is the more profitable company, earning 38.0% net margin versus -1633.1% for Abivax S.A. — meaning it keeps 38.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GYRE leads at 15.3% versus -1602.9% for ABVX. At the gross margin level — before operating expenses — CANF leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is GYRE or ARGX or CANF or AKTX or ABVX more undervalued right now?
On forward earnings alone, argenx SE (ARGX) trades at 25.6x forward P/E versus 45.0x for Gyre Therapeutics, Inc. — 19.4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AKTX: 12601.1% to $30.00.
07Which pays a better dividend — GYRE or ARGX or CANF or AKTX or ABVX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is GYRE or ARGX or CANF or AKTX or ABVX better for a retirement portfolio?
For long-horizon retirement investors, Abivax S.A. (ABVX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.07), +1361% 10Y return). Both have compounded well over 10 years (ABVX: +1361%, GYRE: -92.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between GYRE and ARGX and CANF and AKTX and ABVX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.